drugset / Trial / NCT06057168

Performance of Elucirem in DSC-MRI Perfusion of Brain Gliomas

NCT06057168

Phase 3 Completed 138 enrolled Guerbet
RandomizedParallel-groupSingle-blindDiagnostic

Summary

This trial aimed to study the performance of Elucirem (gadopiclenol) in Dynamic Susceptibility Contrast Magnetic Resonance Imaging (DSC-MRI) perfusion of brain gliomas.

Timeline

Start
2023-09-07
Primary completion
2024-11-28
Completion
2024-11-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Gadopiclenol Diagnostic / imaging agent Intravenous
Comparator Gadoterate meglumine Diagnostic / imaging agent Intravenous